STOCKHOLM, Sweden, Sept. 17, 2003 (PRIMEZONE) -- Active Biotech (Other OTC:ACTBF)(Stockholm Stock Exchange: Acti B) will be presenting the company at the 2003 UBS Global Life Sciences Conference being held September 22-25, at the Plaza Hotel in New York.
This annual conference is attended by approximately 3,000 investment professionals and pharmaceutical decision-makers.
From Active Biotech will be present; Sven Andreasson CEO, Tomas Leanderson CSO and Hans Kolam CFO.
The presentation, scheduled to take place on Tuesday, September 23rd at 2:30 P.M. will cover the development opportunities for Active Biotech's oral multiple sclerosis product laquinimod (SAIK-MS) that recently successfully concluded a phase II study, as well as the ongoing clinical program for the cancer project TTS (Tumor Targeted Superantigens).
Furthermore, an update of the company's phase I studies in prostate cancer and the planned Phase I study in Systemic Lupus Erythematosus (SLE) will be presented.
For more details about Active Biotech and ongoing research project, please visit our web page www.activebiotech.com.
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).